122372-20-7Relevant academic research and scientific papers
COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY
-
Paragraph 00495; 00496, (2018/12/13)
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
cGAS ANTAGONIST COMPOUNDS
-
Paragraph 0260, (2017/11/06)
Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir
Belema, Makonen,Nguyen, Van N.,Bachand, Carol,Deon, Dan H.,Goodrich, Jason T.,James, Clint A.,Lavoie, Rico,Lopez, Omar D.,Martel, Alain,Romine, Jeffrey L.,Ruediger, Edward H.,Snyder, Lawrence B.,Laurent, Denis R. St.,Yang, Fukang,Zhu, Juliang,Wong, Henry S.,Langley, David R.,Adams, Stephen P.,Cantor, Glenn H.,Chimalakonda, Anjaneya,Fura, Aberra,Johnson, Benjamin M.,Knipe, Jay O.,Parker, Dawn D.,Santone, Kenneth S.,Fridell, Robert A.,Lemm, Julie A.,O'Boyle, Donald R.,Colonno, Richard J.,Gao, Min,Meanwell, Nicholas A.,Hamann, Lawrence G.
, p. 2013 - 2032 (2014/04/03)
The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit
ANTIVIRAL COMPOUNDS
-
Page/Page column 78, (2012/09/22)
The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 142, (2011/02/24)
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HCV replication.
HEPATITIS C INHIBITOR COMPOUNDS
-
Page/Page column 21; 22, (2011/08/21)
Compounds of Formula (I): wherein R1, R2, RA, RB, Z1, Z2, Z3, Z4, Z5 and Z6 are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.
COMPOUNDS AND COMPOSITIONS AS MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 INHIBITORS
-
Page/Page column 78-80, (2010/11/17)
Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or di
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 170, (2009/10/09)
The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 103, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 103, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
